Linda Mol

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Journal: Nature

Published: July 22, 2025

Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.

Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 05, 2024

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.

Journal: Nature

Published: January 09, 2024

Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.

Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.

Journal: Clinical colorectal cancer

Published: June 26, 2022

Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.

Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.

Journal: Clinical colorectal cancer

Published: November 30, 2021

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.

Journal: JAMA surgery

Published: October 06, 2021

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.

Journal: BMC cancer

Published: June 22, 2021

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer.

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer.

Journal: Cells

Published: October 23, 2020

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Journal: British journal of cancer

Published: March 12, 2020

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.

Journal: Clinical colorectal cancer

Published: November 10, 2018

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.

Journal: PloS one

Published: December 11, 2017

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.

Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 07, 2017

Showing 1-12 of 21

Last Updated: 09/26/2026